GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » Owner Earnings per Share (TTM)

CEN Biotech (CEN Biotech) Owner Earnings per Share (TTM) : 0.00 (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CEN Biotech's Owner Earnings per Share (TTM) ended in Mar. 2023 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for CEN Biotech's Owner Earnings per Share (TTM) or its related term are showing as below:



CENBF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.375
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

CEN Biotech's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was $-0.02. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.04. It's PE Ratio ratio for today is At Loss.

CEN Biotech's EPS without NRI for the three months ended in Mar. 2023 was $-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.04. It's PE Ratio without NRI ratio for today is At Loss.


CEN Biotech Owner Earnings per Share (TTM) Historical Data

The historical data trend for CEN Biotech's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEN Biotech Owner Earnings per Share (TTM) Chart

CEN Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only - -0.08 0.67 -0.33 -0.02

CEN Biotech Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.05 -0.04 -0.02 -0.02

Competitive Comparison of CEN Biotech's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEN Biotech's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CEN Biotech's Price-to-Owner-Earnings falls into.



CEN Biotech Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

CEN Biotech's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -1.64
Depreciation, Depletion and Amortization 0.41
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.20
Change In Working Capital 0.06
Shares Outstanding (Diluted Average) 65.26

1. Start with "Net Income" from income statement. CEN Biotech's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.64 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. CEN Biotech's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2023 was $0.41 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. CEN Biotech's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.20 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

CEN Biotech's 5-Year Average Maintenance Capital Expenditure = $0.20 Mil

5. "Change In Working Capital" is from cashflow statement. CEN Biotech's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2023 was $0.06 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. CEN Biotech's Shares Outstanding (Diluted Average) for the months ended in Mar. 2023 was 65.256 Mil.

CEN Biotech's Onwer Earnings Per Share for Mar. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -1.636 +0.409+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.2+0.063)/65.256
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.0002/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


CEN Biotech Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of CEN Biotech's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


CEN Biotech (CEN Biotech) Business Description

Traded in Other Exchanges
N/A
Address
3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9
Website
CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.
Executives
Lawrence Lehoux director, officer: Chief Technology Officer 11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas director 23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy director 9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh director 3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne director, officer: Chief Executive Officer 6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain director 18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck director 352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell director, 10 percent owner, officer: CFO Senior Executive VP 2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris director 30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne director, officer: Vice President 1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre director APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban director, 10 percent owner, officer: Chief Executive Officer 888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines